[Skip to Content]
[Skip to Content Landing]
Views 19,574
Citations 0
News From the Food and Drug Administration
March 19, 2019

Breast Implant–Associated Lymphoma

JAMA. 2019;321(11):1042. doi:10.1001/jama.2019.1936

In a recent letter, the FDA encouraged health care professionals to learn more about the association between all breast implants—regardless of filling or texture—and anaplastic large cell lymphoma (ALCL), a type of non-Hodgkin lymphoma.

The letter was prompted by the agency’s analysis of updated medical device reports involving breast implant-associated ALCL as of September 2018. Of the 660 reports received from across the globe since 2010, 457 were unique cases that included 9 patient deaths. Breast implant-associated ALCL was generally found in fibrous scar tissue adjacent to the implant.